Fred. ..well then thats the issue...There is a discrepancy here somewhere. ..they mentioned in the meeting about doing human studies..if yiu recall the one panelist was concerned them being done in Jordan. The issue became as I saw it they didn't have completed the tests fir oral and nasal. The reason being that they were not going for that indication yet and could follow up later. ..I believe that will be the basis of litigation as numbers has just pointed out the pr put out by the company suggested that they were going for indication of oral and nasal. Hence the misleading of shareholders claim.
Market Data 
Markets 
AI
